Immuno-Oncology | Specialty

Combining Nivolumab With Radiation Shows Promise in Melanoma Patients With Brain Mets

February 2nd 2016

Combining nivolumab (Opdivo) with radiation therapy may provide better disease control and prolong overall survival in patients with melanoma whose disease has metastasized to the brain, compared with standard current treatment.

Wolchok on Impact of Nivolumab's Expanded Approval in Melanoma

February 2nd 2016

Jedd D. Wolchok, MD, discusses the implications of the expanded FDA approval of nivolumab, and the potential for the PD-1 inhibitor as both a single agent and as part of a combination regimen in advanced melanoma

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

January 28th 2016

Nivolumab Improves Survival in Phase III Head and Neck Cancer Study

January 28th 2016

Nivolumab has improved overall survival versus investigator's choice of therapy for patients with platinum-refractory squamous cell carcinoma of the head and neck in the phase III CheckMate-141 trial.

PD-1 Inhibitors Make Tremendous Impact in NSCLC, But Questions Remain

January 28th 2016

Renato Martins, MD, discusses what questions still remain regarding PD-L1 as a biomarker, sequencing, and how nivolumab and pembrolizumab compare head-to-head in non–small cell lung cancer.

Expert Assesses Atezolizumab in NSCLC

January 28th 2016

Chandra P. Belani, MD, discusses the impact of clinical trials examining atezolizumab and the role of PD-L1 as a predictive and prognostic biomarker for response to the agent in non–small celll lung cancer.

Promising Immuno-Oncology Approaches in the Management of Squamous Cell Carcinoma of the Head and Neck

January 27th 2016

Substantial evidence exists that a subset of squamous cell cancers of the head and neck display phenotypic changes that predict activity for immune checkpoint inhibitors.

Vaccine Strategy for Biomarker in NSCLC Reaches Phase III Study

January 27th 2016

An emerging vaccine strategy, of TG4010 immunotherapy and first-line chemotherapy, that could target a potential new biomarker in patients with advanced non-small cell lung cancer (NSCLC) has successfully reached a phase III clinical trial, researchers noted.

Mismatch Repair-Deficient GI Tumors Respond to Anti—PD-1 Therapy

January 26th 2016

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.

Avelumab Clinically Active in Advanced Gastric/GEJ Cancer

January 23rd 2016

The investigational anti–PD-L1 antibody avelumab demonstrated clinical activity as a second-line and maintenance therapy for patients with unresectable gastric or gastroesophageal junction cancer.

FDA Expands Nivolumab's Frontline Melanoma Approval to Include BRAF-Mutant Patients

January 23rd 2016

The FDA has expanded the frontline melanoma indications for nivolumab as a single agent and in combination with ipilimumab to include patients with BRAF mutations.

Nivolumab Shows Clinical Activity in Gastric Cancer

January 22nd 2016

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

Pembrolizumab Active in Advanced Esophageal Carcinoma

January 22nd 2016

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

Nivolumab Active in Heavily Pretreated Esophageal Cancer

January 22nd 2016

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

Radiation/Immunotherapy Combos Slow to Gain Traction, But Have Potential in Prostate Cancer

January 20th 2016

Steven Finkelstein, MD, explains why radiation and immunotherapy may be an effective combination in prostate cancer.

High T-Cell Diversity Linked to Better Prognosis in mRCC

January 14th 2016

The VEGFR inhibitor pazopanib was efficacious independent of T-cell receptor–gamma entropy in metastatic renal cell carcinoma setting.

Emerging Targets in NSCLC Treatment

January 13th 2016

Subtypes in NSCLC: BRAF and RET

January 13th 2016

Approval of Third-Generation TKIs for EGFR-Targeted Therapies

January 13th 2016